Incyte targeted drug plus chemo shows durable responses in pancreatic cancer at ESMO

Incyte presented data at ESMO showing its targeted therapy combined with chemotherapy produced lasting tumor responses in a subset of pancreatic cancer patients. The durability and subset specificity are notable but full efficacy and safety data remain to be published. This could shift treatment paradigms if confirmed in later trials.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works